CAJ | 학술논문

目的：观察以雷贝拉唑与加替沙星为基础的三联疗法根除幽门螺杆菌（HP）的疗效及不良反应。方法选取2011年2月至2013年3月医院收治的120例HP感染患者，按照随机数字表法分为3组，每组40例，A组给予雷贝拉唑、加替沙星联合甲硝唑治疗，B组给予雷贝拉唑、加替沙星联合阿莫西林治疗，C组给予雷贝拉唑、甲硝唑联合阿莫西林治疗，疗程均为2周，停药4周后复查患者胃镜或14C－尿素呼气试验。结果治疗后3组患者上腹部疼痛、上腹部饱胀、反酸、嗝气症状积分均优于治疗前（ P<0.05）。A组临床治疗有效率为97.50%，B组为95.00%，均高于C组的80.00%（ P<0.05）。A组、B组患者的HP根除率分别为95.00%和92.50%，均高于C组的75.00%（ P<0.05）。结论以雷贝拉唑与加替沙星为基础的三联疗法可有效根除HP，提高疗效，降低不良反应发生率。
목적：관찰이뢰패랍서여가체사성위기출적삼련요법근제유문라간균（HP）적료효급불량반응。방법선취2011년2월지2013년3월의원수치적120례HP감염환자，안조수궤수자표법분위3조，매조40례，A조급여뢰패랍서、가체사성연합갑초서치료，B조급여뢰패랍서、가체사성연합아막서림치료，C조급여뢰패랍서、갑초서연합아막서림치료，료정균위2주，정약4주후복사환자위경혹14C－뇨소호기시험。결과치료후3조환자상복부동통、상복부포창、반산、격기증상적분균우우치료전（ P<0.05）。A조림상치료유효솔위97.50%，B조위95.00%，균고우C조적80.00%（ P<0.05）。A조、B조환자적HP근제솔분별위95.00%화92.50%，균고우C조적75.00%（ P<0.05）。결론이뢰패랍서여가체사성위기출적삼련요법가유효근제HP，제고료효，강저불량반응발생솔。
Objective To investigate the efficacy and adverse reactions of the triple therapy based on rabeprazole and gatifloxacin in the eradication of Helicobacter pylori ( HP ) . Methods 120 cases of gastritis conforming to HP infection in our hospital from February 2011 to March 2013 were selected and divided into the three groups of A, B and C according to the random number table method, 40 cases in each group. The group A group was given the treatment of rabeprazole, gatifloxacin combined with metronidazole, the group B was given the treatment of rabeprazole, gatifloxacin combined with amoxicillin and the group C was treated with rabeprazole, metronida-zole combined with amoxicillin. The course of treatment was 2 weeks. The re-examination of gastroscopy or 14C-UBT was performed after 4 weeks of drug withdrawal. Results The symptom scores of upper abdominal pain, abdominal fullness, acid regurgitation and belching after treatment in the three groups were better than those before treatment, the differences among 3 groups were statistically significant ( P < 0. 05 ) . The effective rate was 97. 50% in the group A and 95. 00% in the group B, which higher than 80. 00% in the group C ( P < 0. 05 ) . The HP eradication rates in the group A and B were 95. 00% and 92. 50% respectively, which were higher than 75. 00% in the group C ( P < 0. 05 ) . Conclusion : The triple therapy based on rabeprazole and gatifloxacin can effectively eradicate HP, improves the curative efficacy, reduces the incidence rate of adverse reactions, and is worthy of clinical promotion.